Sanofi Pasteur Announces Publication of Positive Data for Fluzone High-Dose Vaccine in the New England Journal of Medicine

Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older August 13, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that FluzoneĀ® High-Dose (Influenza Vaccine) was …